Physician profile
Sara Levine
NPI 1144298571
$5,344.42
in general payments reported to CMS, 2019-2025
26 companies · $1,258 in 2025
The $1,258 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,057 · 2020: $128 · 2022: $471 · 2023: $997 · 2024: $1,433 · 2025: $1,258.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,670 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $18.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,669.84 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $18.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $978.63 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $876.66 | 2019-2025 | Otezla, Repatha, Repatha |
| Lilly USA, LLC | $674.69 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Novo Nordisk INC | $424.66 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Novartis Pharmaceuticals Corporation | $342.61 | 2022-2025 | |
| Exact Sciences Corporation | $334.84 | 2023-2025 | Cologuard Collection Kit |
| Abbvie INC. | $304.52 | 2022-2025 | |
| Pfizer INC. | $255.04 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $128.74 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.07 | 2019-2025 | Jardiance |
| Idorsia Pharmaceuticals US INC | $107.76 | 2023-2024 | Quviviq |
| Currax Pharmaceuticals LLC | $106.59 | 2019-2023 | Contrave, Onzetra Xsail, Nexlizet |
| Kowa Pharmaceuticals America, INC. | $100.22 | 2019-2023 | Livalo |
| Teva Pharmaceuticals USA, INC. | $96.97 | 2019-2024 | Uzedy |
| Merck Sharp & Dohme LLC | $87.88 | 2019-2024 | Gardasil 9, Gardasil, Capvaxive |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $78.25 | 2019-2020 | |
| Viatris Specialty LLC | $59.72 | 2025 | Yupelri |
| Vivus LLC | $57.10 | 2019-2024 | Qsymia |
| Glaxosmithkline, LLC. | $40.49 | 2024 | Shingrix |
| Genentech USA, INC. | $38.97 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $31.61 | 2019 | |
| Abbott Laboratories | $22.71 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $21.01 | 2023 | Rexulti |
| Medicure Pharma INC. | $18.86 | 2024 | Zypitamag |
| Amneal Pharmaceuticals LLC | $17.50 | 2019 | |
| Alfasigma USA, INC. | $16.32 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Levine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.